Castle Biosciences, Inc. cash flow to debt ratio of 174.32% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Castle Biosciences, Inc.'s free cash flow has decreased -22.48% from $36.54M last year to $28.33M, signaling decreasing performance

Castle Biosciences, Inc.'s debt to equity ratio is 0.08, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Castle Biosciences, Inc.'s debt has increased relative to shareholder equity from 0.06 last year to 0.08 today, signaling weakened financials

Castle Biosciences, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Castle Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Castle Biosciences, Inc.'s profit margin has decreased (-168.71%) in the last year from 5.49% to -3.77%, signaling decreasing performance

Castle Biosciences, Inc.'s short-term assets of $361.10M exceed its short-term liabilities of $68.68M

Castle Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Castle Biosciences, Inc.'s return on equity of -2.77%, is lower than 15.00%, indicating bad performance

Castle Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Castle Biosciences, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Castle Biosciences, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Castle Biosciences, Inc. has a free cash flow yield of 4.04%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Castle Biosciences, Inc.'s yearly earnings has decreased -232.41% since last year from $18.25M to $-24.16M, signaling decreasing performance

Castle Biosciences, Inc.'s yearly revenue has increased 3.66% since last year from $332.07M to $344.23M, signaling increasing performance

ROIC -4.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Castle Biosciences, Inc.'s 3-year revenue CAGR of 35.94% is positive, indicating growing revenue over the past 3 years

Castle Biosciences, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Castle Biosciences, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Castle Biosciences, Inc. is overvalued relative to its fair value price of 19.60 based on Discounted Cash Flow model

Castle Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Castle Biosciences, Inc. is overvalued relative to its fair value price of 5.36 based on EBITDA multiple model

Castle Biosciences, Inc. has an EV/EBITDA ratio of 54.78x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Castle Biosciences, Inc. is overvalued relative to its fair value price of -71.09 based on Earnings Fair Value model

Castle Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Castle Biosciences, Inc. has a price-to-book ratio of 1.50x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Castle Biosciences, Inc. has a price-to-sales ratio of 2.03x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue